AUG 28 2026
Protagonist Therapeutics — Mimrylo (rusfertide) $PTGX
for polycythemia vera
About
Polycythemia vera is a rare blood cancer in which the bone marrow produces too many red blood cells, thickening the blood and raising the risk of clots, strokes, and heart attacks. Mimrylo (rusfertide) is a lab-made peptide given by injection that mimics hepcidin, the body's natural hormone for limiting how much iron is available for red blood cell production. By copying that iron-restricting signal, Mimrylo may help keep red blood cell counts under control and ease symptoms for people living with this condition.
Pivotal trial
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Mimrylo
- Takeda wins FDA approval for MIMRYLO, triggers $275m payout to Protagonist - scanx.trade
- Onco360® Has Been Selected as Part of an Ultra-Narrow Specialty Pharmacy Network for MIMRYLO™ (rusfertide) - Yahoo Finance
- MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? - Yahoo Finance
- Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval? - Yahoo Finance
- The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones - Yahoo Finance
Sponsor Watch — recent news on Protagonist Therapeutics
- Protagonist Therapeutics Announces $300 Million Share Repurchase Program
- MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
- The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones
- Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval?
- Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment